Jane T. Kurtzman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jane T. Kurtzman has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Steven B. Brandes
Department of Urology, Columbia University Irving Medical Center, New York, USA
6 shared publications Ruth Blum
Department of Urology, Columbia University Irving Medical Center, New York, USA
5 shared publicationsPreston Kerr
Department of Urology, Columbia University Irving Medical Center, New York, USA
3 shared publicationsChristopher B. Anderson
Department of Urology, Columbia University Irving Medical Center, New York, New York
2 shared publicationsJames M. McKiernan
Department of Urology, Columbia University Irving Medical Center, New York, New York
2 shared publicationsS. Brandes
2 shared publications
Latest Publications
- Open Access
Validation and testing of an in vitro model to study medical treatments for anterior urethral stricture disease: assessing the potential efficacy of phosphodiesterase-4 (PDE4) inhibition and testosterone
Objective: To 1) determine the expression and distribution of all PDE4 isozymes (A-D) along the length of the anterior urethra, 2) culture fibroblasts and epithelial cells from healthy and strictured urethras, 3) investigate an in vitro model of anterior urethral stricture disease (aUSD), and 4) assess the therapeutic potential of phosphodiesterase-4 (PDE4) inhibitors and testosterone compared to paclitaxel. Methods: The presence and relative abundance of PDE4 isozymes (A-D) was confirmed using immunohistochemistry on 5 male cadaveric urethras. Human urethral fibroblasts (FBs) were cultured from healthy control urethras of patients undergoing vaginoplasty (n=3) and from idiopathic bulbar urethral strictures (L2S1E2) of patients undergoing urethroplasty (n=3). Epithelial cells (ECs) were cultured from a healthy control urethra and two urethral strictures. To investigate a model of aUSD, Control FBs were stimulated with TGFβ1 and compared to Stricture FBs on assays of cell proliferation and expression of genes relevant to aUSD pathophysiology. To test therapeutics, Stricture FBs were treated with the PDE4 inhibitor, roflumilast, testosterone (T), or paclitaxel and compared to Control FBs on the previously mentioned assays and cell viability. Results: PDE4- A, B, and D were detected along the length of the urethra. Expression levels did not differ between urethral regions. TGFβ1 altered proliferation and gene expression in a dose-dependent manner. Roflumilast and T preserved cell viability and proliferation and decreased expression of genes positively associated with auSD. Conclusion: Urethral FBs and ECs can be cultured from healthy and strictured surgical specimens, enabling in vitro research. PDE4 inhibitors and T may be non-cytotoxic alternatives or additions to paclitaxel for aUSD. Highlights: PDE4 isozymes A, B, and D are expressed in adult anterior urethras PDE4 is expressed equally from proximal bulbar to meatal urethra Epithelial cells and fibroblasts can be cultured from healthy and stricture urethra TGFβ1 may not be an optimal method to model aUSD in vitro Unlike paclitaxel, roflumilast and testosterone are not toxic to urethral cells
Open AccessValidation and testing of an in vitro model to study medical treatments for anterior urethral stricture disease: assessing the potential efficacy of phosphodiesterase-4 (PDE4) inhibition and testosterone
Objective: To 1) determine the expression and distribution of all PDE4 isozymes (A-D) along the length of the anterior urethra, 2) culture fibroblasts and epithelial cells from healthy and strictured urethras, 3) investigate an in vitro model of anterior urethral stricture disease (aUSD), and 4) assess the therapeutic potential of phosphodiesterase-4 (PDE4) inhibitors and testosterone compared to paclitaxel. Methods: The presence and relative abundance of PDE4 isozymes (A-D) was confirmed using immunohistochemistry on 5 male cadaveric urethras. Human urethral fibroblasts (FBs) were cultured from healthy control urethras of patients undergoing vaginoplasty (n=3) and from idiopathic bulbar urethral strictures (L2S1E2) of patients undergoing urethroplasty (n=3). Epithelial cells (ECs) were cultured from a healthy control urethra and two urethral strictures. To investigate a model of aUSD, Control FBs were stimulated with TGFβ1 and compared to Stricture FBs on assays of cell proliferation and expression of genes relevant to aUSD pathophysiology. To test therapeutics, Stricture FBs were treated with the PDE4 inhibitor, roflumilast, testosterone (T), or paclitaxel and compared to Control FBs on the previously mentioned assays and cell viability. Results: PDE4- A, B, and D were detected along the length of the urethra. Expression levels did not differ between urethral regions. TGFβ1 altered proliferation and gene expression in a dose-dependent manner. Roflumilast and T preserved cell viability and proliferation and decreased expression of genes positively associated with auSD. Conclusion: Urethral FBs and ECs can be cultured from healthy and strictured surgical specimens, enabling in vitro research. PDE4 inhibitors and T may be non-cytotoxic alternatives or additions to paclitaxel for aUSD. Highlights: PDE4 isozymes A, B, and D are expressed in adult anterior urethras PDE4 is expressed equally from proximal bulbar to meatal urethra Epithelial cells and fibroblasts can be cultured from healthy and stricture urethra TGFβ1 may not be an optimal method to model aUSD in vitro Unlike paclitaxel, roflumilast and testosterone are not toxic to urethral cells
- Open Access
- 1 September 2024
- Published by Wolters Kluwer Health in JU Open Plus
- Vol. 2 (9)
Long-Term Oncologic Outcomes in Patients With Muscle Invasive Bladder Cancer Misclassified as Achieving a Complete Clinical Response to Neoadjuvant Chemotherapy
Introduction: Correctly classifying patients with muscle invasive bladder cancer (MIBC) as achieving a complete clinical response (CCR) to neoadjuvant chemotherapy (NAC) is challenging without radical cystectomy (RC) pathology. The accuracy of clinical staging following NAC is debated, and the risk of occult residual MIBC is real. We present the rate and oncologic outcomes of patients who were misclassified as achieving a CCR to NAC. Materials and Methods: We utilized our prospective database of patients who achieved a CCR to NAC and elected active surveillance (AS). Patients with intravesical MIBC within 6 months of CCR classification were defined as potentially misclassified (mCCR). We used Kaplan-Meier curves to assess overall (OS), cancer-specific (CSS), and metastasis-free (MFS) survival and log-rank tests to evaluate differences between cohorts. Results: Fifty-four patients, median age of 70 years and follow-up of 49 months, were included. Six patients (11%) were mCCR, and all underwent delayed RC at a mean of 4.3 months after CCR classification. Pre-NAC hydronephrosis was more common in mCCR patients (67% vs 8%, P < .01). Five-year OS, CSS, and MFS for mCCR patients were 63% each, compared with 80%, 89%, and 93%, for the remaining patients. Log-rank tests demonstrated significantly lower OS (P = .03) and MFS (P = .05) in mCCR patients. Conclusions: We observed an 11% CCR misclassification rate. While mCCR patients had significantly worse OS and MFS compared with correctly classified CCR patients, we cannot know for certain how survival outcomes would have changed with immediate RC. Our findings are useful when describing the risks of misclassification to CCR patients contemplating AS.
- 1 September 2024
- Published by Wolters Kluwer Health in JU Open Plus
- Vol. 2 (9)
Open AccessLong-Term Oncologic Outcomes in Patients With Muscle Invasive Bladder Cancer Misclassified as Achieving a Complete Clinical Response to Neoadjuvant Chemotherapy
Introduction: Correctly classifying patients with muscle invasive bladder cancer (MIBC) as achieving a complete clinical response (CCR) to neoadjuvant chemotherapy (NAC) is challenging without radical cystectomy (RC) pathology. The accuracy of clinical staging following NAC is debated, and the risk of occult residual MIBC is real. We present the rate and oncologic outcomes of patients who were misclassified as achieving a CCR to NAC. Materials and Methods: We utilized our prospective database of patients who achieved a CCR to NAC and elected active surveillance (AS). Patients with intravesical MIBC within 6 months of CCR classification were defined as potentially misclassified (mCCR). We used Kaplan-Meier curves to assess overall (OS), cancer-specific (CSS), and metastasis-free (MFS) survival and log-rank tests to evaluate differences between cohorts. Results: Fifty-four patients, median age of 70 years and follow-up of 49 months, were included. Six patients (11%) were mCCR, and all underwent delayed RC at a mean of 4.3 months after CCR classification. Pre-NAC hydronephrosis was more common in mCCR patients (67% vs 8%, P < .01). Five-year OS, CSS, and MFS for mCCR patients were 63% each, compared with 80%, 89%, and 93%, for the remaining patients. Log-rank tests demonstrated significantly lower OS (P = .03) and MFS (P = .05) in mCCR patients. Conclusions: We observed an 11% CCR misclassification rate. While mCCR patients had significantly worse OS and MFS compared with correctly classified CCR patients, we cannot know for certain how survival outcomes would have changed with immediate RC. Our findings are useful when describing the risks of misclassification to CCR patients contemplating AS.
- Open Access
- 22 November 2023
- Published by Elsevier in European Urology Open Science
- Vol. 57, S438-S439
Urinary deversion as a last resort in patients with failed artificial urinary sphincter implantation
- 22 November 2023
- Published by Elsevier in European Urology Open Science
- Vol. 57, S438-S439
Open AccessUrinary deversion as a last resort in patients with failed artificial urinary sphincter implantation
- 3 June 2023
- Published by Elsevier in The American Journal of Surgery
- Vol. 226 (5) , 717-720
Oocyte cryopreservation during graduate medical training: A survey of trainees
- 3 June 2023
- Published by Elsevier in The American Journal of Surgery
- Vol. 226 (5) , 717-720
Oocyte cryopreservation during graduate medical training: A survey of trainees
- 7 February 2023
- Published by Springer Nature in World Journal of Urology
- Vol. 41 (3) , 879-884
The role of transcorporal cuff placement in high-risk and ultra-high-risk patients: are they actually helpful?
Purpose To assess the incidence of artificial urinary sphincter (AUS) explant in high-risk patients and to evaluate the relationship between transcorporal cuff (TCC) placement and explant risk in this population. Methods We retrospectively reviewed all AUS insertions performed on high-risk patients by a single surgeon from 2010 to 2020. “High-risk” was defined as having ≥ 1 urethral risk factor: pelvic radiation, urethroplasty, recalcitrant urethral/bladder neck stenosis, urethral stenting, or previous AUS erosion/infection. Patients with ≥ 2 factors were “ultra-high-risk.” Time-to-event analyses were used to assess all-cause-, infection/erosion-related-, and mechanical failure-related explant-free survival. Subgroup analyses were performed for patients with a history of radiation and urethral dissection. Results The final cohort included 68 men, mean age of 67 years (SD 11), and 77 AUS cuffs. Mean follow-up was 32 months (IQR 6–50). 29% of cuffs (n = 22) were transcorporal. 32 cuffs (42%) were explanted. All-cause explant-free survival was 64% at 1 year and 52% at 2 years. Classification as “ultra-high-risk” was not associated with explant risk (all p-values > 0.05). TCC placement was associated with an increased risk of explant for infection/erosion across all patients (HR 2.74, p = 0.03) and in radiated patients (n = 50; HR 4.1, p = 0.04), but not in patients with prior urethral dissection (n = 52; HR 1.98, p = 0.21). Conclusion High-risk patients have a high rate of AUS explant and TCC placement may not be protective in this population. TCC placement was associated with an increased risk of infection/erosion in radiated patients, but not in those with a history of open urethral surgery.
- 7 February 2023
- Published by Springer Nature in World Journal of Urology
- Vol. 41 (3) , 879-884
The role of transcorporal cuff placement in high-risk and ultra-high-risk patients: are they actually helpful?
Purpose To assess the incidence of artificial urinary sphincter (AUS) explant in high-risk patients and to evaluate the relationship between transcorporal cuff (TCC) placement and explant risk in this population. Methods We retrospectively reviewed all AUS insertions performed on high-risk patients by a single surgeon from 2010 to 2020. “High-risk” was defined as having ≥ 1 urethral risk factor: pelvic radiation, urethroplasty, recalcitrant urethral/bladder neck stenosis, urethral stenting, or previous AUS erosion/infection. Patients with ≥ 2 factors were “ultra-high-risk.” Time-to-event analyses were used to assess all-cause-, infection/erosion-related-, and mechanical failure-related explant-free survival. Subgroup analyses were performed for patients with a history of radiation and urethral dissection. Results The final cohort included 68 men, mean age of 67 years (SD 11), and 77 AUS cuffs. Mean follow-up was 32 months (IQR 6–50). 29% of cuffs (n = 22) were transcorporal. 32 cuffs (42%) were explanted. All-cause explant-free survival was 64% at 1 year and 52% at 2 years. Classification as “ultra-high-risk” was not associated with explant risk (all p-values > 0.05). TCC placement was associated with an increased risk of explant for infection/erosion across all patients (HR 2.74, p = 0.03) and in radiated patients (n = 50; HR 4.1, p = 0.04), but not in patients with prior urethral dissection (n = 52; HR 1.98, p = 0.21). Conclusion High-risk patients have a high rate of AUS explant and TCC placement may not be protective in this population. TCC placement was associated with an increased risk of infection/erosion in radiated patients, but not in those with a history of open urethral surgery.
- 1 November 2022
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 208 (5) , 1083-1089
Evaluating Tools for Characterizing Anterior Urethral Stricture Disease: A Comparison of the LSE System and the Urethral Stricture Score
Introduction: We evaluated if scores generated by the LSE Classification System and the U-Score (US) system are associated with intraoperative surgical complexity and stricture recurrence risk. Materials and Methods: We retrospectively reviewed all consenting patients who underwent single-stage anterior urethroplasty by a single surgeon at two institutions. US and a numerical LSE “score” (LSE) was calculated for each patient. Pearson’s correlation and linear regression analyses were used to assess for a relationship between increasing US and LSE and surgical complexity. Kaplan Meier curves and Cox Proportional hazard regression models were used to assess for an association between US and LSE and stricture recurrence risk. Results: 187 patients, mean age: 48 years-old (SD 16) and mean stricture length: 4.2cm (SD 3.3) were included. Mean follow-up was 21 months. 46 patients recurred over time. We found a strong positive, linear correlation between US and LSE (p <0.001). Both increasing US and LSE independently linearly correlated with increasing surgical complexity (both p <0.0001). Univariable analysis demonstrated that increasing LSE was significantly associated with an increased risk of stricture recurrence (HR 1.2, p=0.02) but US was not. Patients with a high LSE (≥7) were nearly 3-times as likely to recur than patients with a low LSE (HR 2.7, p=0.001). Conclusions: Increasing US and LSE scores are both associated with increasing surgical complexity, but only LSE is associated with stricture recurrence risk. Conversion of the LSE Classification System into a numeric score adds functionality to this novel system.
- 1 November 2022
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 208 (5) , 1083-1089
Evaluating Tools for Characterizing Anterior Urethral Stricture Disease: A Comparison of the LSE System and the Urethral Stricture Score
Introduction: We evaluated if scores generated by the LSE Classification System and the U-Score (US) system are associated with intraoperative surgical complexity and stricture recurrence risk. Materials and Methods: We retrospectively reviewed all consenting patients who underwent single-stage anterior urethroplasty by a single surgeon at two institutions. US and a numerical LSE “score” (LSE) was calculated for each patient. Pearson’s correlation and linear regression analyses were used to assess for a relationship between increasing US and LSE and surgical complexity. Kaplan Meier curves and Cox Proportional hazard regression models were used to assess for an association between US and LSE and stricture recurrence risk. Results: 187 patients, mean age: 48 years-old (SD 16) and mean stricture length: 4.2cm (SD 3.3) were included. Mean follow-up was 21 months. 46 patients recurred over time. We found a strong positive, linear correlation between US and LSE (p <0.001). Both increasing US and LSE independently linearly correlated with increasing surgical complexity (both p <0.0001). Univariable analysis demonstrated that increasing LSE was significantly associated with an increased risk of stricture recurrence (HR 1.2, p=0.02) but US was not. Patients with a high LSE (≥7) were nearly 3-times as likely to recur than patients with a low LSE (HR 2.7, p=0.001). Conclusions: Increasing US and LSE scores are both associated with increasing surgical complexity, but only LSE is associated with stricture recurrence risk. Conversion of the LSE Classification System into a numeric score adds functionality to this novel system.
- 1 September 2022
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 208 (3) , 511-513
Intraoperative Modification of Artificial Urinary Sphincter Cuffs: Achieving Enhanced Cuff Fit
- 1 September 2022
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 208 (3) , 511-513
Intraoperative Modification of Artificial Urinary Sphincter Cuffs: Achieving Enhanced Cuff Fit
- 1 February 2022
- Published by SAGE Publications in Journal of Endourology
- Vol. 36 (2) , 224-230
Hospital Ownership, Geographic Region, Patient Age, Comorbidities, and Insurance Status Appear to Influence Patient Selection Robot-Assisted Ureteral Reimplantation for Benign Disease: A Population-Based Analysis
Background: Robot-assisted ureteral reimplantation (RAUR) is a relatively new minimally invasive procedure. As such, research is lacking, and the largest adult cohort studies include fewer than 30 patients. Our aim was to be the first population-based study to report on national utilization trends, factors associated with patient selection, inpatient outcomes, and the relative cost of RAUR for adults with benign ureteral disease (BUD). Materials and Methods: The National Inpatient Sample (2010–2015) was queried to identify all elective, nontransplant-related, open and robot-assisted reimplants for adult BUD. Survey-weighted logistic regression using Akaike Information Criterion identified patient-/hospital-level factors associated with robotic procedure. Survey-weighted regression models examined the association of robotic procedure with outcomes and charges. Results: A weighted total of 9088 cases were included: 1688 (18.6%) robot assisted and 7400 (81.4%) open. There were significantly increased odds of RAUR across consecutive years (odds ratio [OR] = 3.0, p < 0.001) and among patients operated on at private for-profit hospitals (OR: 2.1; p = 0.01), but significantly decreased odds among older patients (OR = 0.98, p < 0.001), those with Medicaid (OR = 0.5, p = 0.02), those with 2+ comorbidities (OR = 0.6, p = 0.009), and those operated on in western (OR = 0.5; p = 0.005) states. RAUR was significantly associated with a reduced length-of-stay (incidence rate ratio: 0.60; p < 0.001), decreased odds of blood transfusion (OR = 0.40; p < 0.001), and a lower mean ratio of total hospital charges (ratio: 0.71; p = 0.006). Conclusions: This is the first population-based study to report on the utilization and clinical benefits of RAUR for adult BUD. Open reimplantation remains the most common surgical technique utilized, despite the potential benefits of RAUR. Future research is needed to explore the mechanisms behind patient-/hospital-level factors and surgical selection. Work to investigate potential barriers in access to robotic procedure can help us provide equitable care across patient populations.
- 1 February 2022
- Published by SAGE Publications in Journal of Endourology
- Vol. 36 (2) , 224-230
Hospital Ownership, Geographic Region, Patient Age, Comorbidities, and Insurance Status Appear to Influence Patient Selection Robot-Assisted Ureteral Reimplantation for Benign Disease: A Population-Based Analysis
Background: Robot-assisted ureteral reimplantation (RAUR) is a relatively new minimally invasive procedure. As such, research is lacking, and the largest adult cohort studies include fewer than 30 patients. Our aim was to be the first population-based study to report on national utilization trends, factors associated with patient selection, inpatient outcomes, and the relative cost of RAUR for adults with benign ureteral disease (BUD). Materials and Methods: The National Inpatient Sample (2010–2015) was queried to identify all elective, nontransplant-related, open and robot-assisted reimplants for adult BUD. Survey-weighted logistic regression using Akaike Information Criterion identified patient-/hospital-level factors associated with robotic procedure. Survey-weighted regression models examined the association of robotic procedure with outcomes and charges. Results: A weighted total of 9088 cases were included: 1688 (18.6%) robot assisted and 7400 (81.4%) open. There were significantly increased odds of RAUR across consecutive years (odds ratio [OR] = 3.0, p < 0.001) and among patients operated on at private for-profit hospitals (OR: 2.1; p = 0.01), but significantly decreased odds among older patients (OR = 0.98, p < 0.001), those with Medicaid (OR = 0.5, p = 0.02), those with 2+ comorbidities (OR = 0.6, p = 0.009), and those operated on in western (OR = 0.5; p = 0.005) states. RAUR was significantly associated with a reduced length-of-stay (incidence rate ratio: 0.60; p < 0.001), decreased odds of blood transfusion (OR = 0.40; p < 0.001), and a lower mean ratio of total hospital charges (ratio: 0.71; p = 0.006). Conclusions: This is the first population-based study to report on the utilization and clinical benefits of RAUR for adult BUD. Open reimplantation remains the most common surgical technique utilized, despite the potential benefits of RAUR. Future research is needed to explore the mechanisms behind patient-/hospital-level factors and surgical selection. Work to investigate potential barriers in access to robotic procedure can help us provide equitable care across patient populations.